加载中
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
收盘时
US$6.77
−US$0.17 · -2.45%
盘后
US$6.77
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日内区间
当前US$6.77
52周区间
当前US$6.77
盘中时间采用ET。市场数据可能有所延迟。
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
日内区间
当前US$6.77
52周区间
当前US$6.77
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 销货成本 | 259.7万 USD | — | — | — | — |
| 毛利 | −259.7万 USD | 25.1万 USD | 3349.2万 USD | 493.1万 USD | 200.2万 USD |
| 研究与开发 | 6954万 USD | 5032.8万 USD | 5025.1万 USD | 4398.4万 USD | 4241万 USD |
| 销售、一般及管理费用 | 2027万 USD | 1720.5万 USD | 1391.2万 USD | 2077.6万 USD | 1286.4万 USD |
| 营业费用 | 8801.3万 USD | 6753.3万 USD | 6416.3万 USD | 6476万 USD | 5527.4万 USD |
| 利息收入 | 595.9万 USD | 534.9万 USD | 253.5万 USD | 129.4万 USD | — |
| 折旧和摊销 | 259.7万 USD | 243.1万 USD | 226.6万 USD | 115.8万 USD | 24.8万 USD |
| 营业利润 | −9061万 USD | −6728.2万 USD | −3067.1万 USD | −5982.9万 USD | −5327.2万 USD |
| 净利润 | −8386.5万 USD | −5849.3万 USD | −2769.6万 USD | −5838.8万 USD | −7182.5万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$37.50
上涨空间 453.91%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
